scispace - formally typeset
D

Dimitrios P. Kontoyiannis

Researcher at University of Texas MD Anderson Cancer Center

Publications -  612
Citations -  32185

Dimitrios P. Kontoyiannis is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Aspergillosis & Cancer. The author has an hindex of 94, co-authored 578 publications receiving 27374 citations. Previous affiliations of Dimitrios P. Kontoyiannis include University of Texas Health Science Center at Houston & University of Houston.

Papers
More filters
Journal ArticleDOI

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

J. Peter Donnelly, +64 more
TL;DR: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Journal ArticleDOI

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

TL;DR: The results support the use of isavuconazole for the primary treatment of patients with invasive mould disease and non-inferiority was shown.
Journal ArticleDOI

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

TL;DR: An expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes.
Journal ArticleDOI

Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia Species

TL;DR: An overview of the epidemiology, clinical manifestations, diagnosis of, treatment of, and prognosis for unusual Mucormycetes infections (non-Rhizopus, -Mucor, and -Lichtheimia species) is provided.